Philippe M Loiseau

List of Publications by Year
in descending order

191	5,393	87888 38	128289 60
papers	citations	h-index	g-index

205	205	205	6773
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Minor Impact of A258D Mutation on Biochemical and Enzymatic Properties of Leishmania infantum GDP-Mannose Pyrophosphorylase. Microorganisms, 2022, 10, 231.	3.6	2
2	The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates. Molecules, 2022, 27, 2313.	3.8	9
3	Targeting chalcone binding sites in living Leishmania using a reversible fluorogenic benzochalcone probe. Biomedicine and Pharmacotherapy, 2022, 149, 112784.	5.6	2
4	Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. Pharmaceutics, 2022, 14, 989.	4.5	14
5	Pharmacokinetics, biodistribution, and activity of Amphotericin B-loaded nanocochleates on the Leishmania donovani murine visceral leishmaniasis model. International Journal of Pharmaceutics, 2022, 624, 121985.	5.2	2
6	InÂvitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L.Âmajor casein kinase 1 inhibition. European Journal of Medicinal Chemistry, 2021, 210, 112956.	5.5	14
7	In vitro antileishmanial potentialities of essential oils from Citrus limon and Pistacia lentiscus harvested in Tunisia. Parasitology Research, 2021, 120, 1455-1469.	1.6	15
8	Alkyl-Resorcinol Derivatives as Inhibitors of GDP-Mannose Pyrophosphorylase with Antileishmanial Activities. Molecules, 2021, 26, 1551.	3.8	5
9	Drugs used for the treatment of cerebral and disseminated infections caused by freeâ€living amoebae. Clinical and Translational Science, 2021, 14, 791-805.	3.1	23
10	An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 2021, 76, 2640-2650.	3.0	7
11	Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis. PLoS Neglected Tropical Diseases, 2021, 15, e0009627.	3.0	11
12	Anti-protozoal and anti-fungal evaluation of 3,5-disubstituted 1,2-dioxolanes. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128196.	2.2	5
13	Trichomonas vaginalis Motility Is Blocked by Drug-Free Thermosensitive Hydrogel. ACS Infectious Diseases, 2020, 6, 114-123.	3.8	5
14	Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections. Molecules, 2020, 25, 5075.	3.8	18
15	Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis. Molecules, 2020, 25, 4123.	3.8	5
16	A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020, 586, 119390.	5.2	29
17	Apoprunellelactone (APL), an antiprotozoal lactone from the stem barks ofIsolona cooperiHutch. & Dalziel (Annonaceae). Natural Product Research, 2020, 35, 1-8.	1.8	1
18	Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against Leishmania donovani. Molecules, 2020, 25, 465.	3.8	25

#	Article	IF	Citations
19	Inhibition of in vitro Ebola infection by anti-parasitic quinoline derivatives. F1000Research, 2020, 9, 268.	1.6	7
20	Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opinion on Drug Delivery, 2019, 16, 1063-1079.	5.0	43
21	Synthesis and biological evaluation against Leishmania donovani of novel hybrid molecules containing indazole-based 2-pyrone scaffolds. MedChemComm, 2019, 10, 120-127.	3.4	7
22	GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 186.	3.9	7
23	Topically Applied Chitosan-Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Cutaneous Leishmaniasis by Accelerating Lesion Healing and Reducing the Parasitic Load. ACS Applied Bio Materials, 2019, 2, 2573-2586.	4.6	16
24	Spermine-NBD as fluorescent probe for studies of the polyamine transport system in Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1710-1713.	2.2	5
25	Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets. Molecules, 2019, 24, 1282.	3.8	15
26	Combination of amphotericin B and chitosan platelets for the treatment of experimental cutaneous leishmaniasis: Histological and immunohistochemical examinations. Journal of Drug Delivery Science and Technology, 2019, 50, 34-41.	3.0	9
27	Synthesis and antikinetoplastid evaluation of bis(benzyl)spermidine derivatives. European Journal of Medicinal Chemistry, 2018, 150, 655-666.	5.5	8
28	Synthetic Polysaccharides as Drug Carriers: Synthesis of Polyglucose-Amphotericin B Conjugates and In Vitro Evaluation of Their Anti-Fungal and Anti-Leishmanial Activities. Journal of Nanoscience and Nanotechnology, 2018, 18, 2405-2414.	0.9	16
29	New Water-Soluble Polymeric Prodrugs of 2-n-propylquinoline: Synthesis and Evaluation of In Vitro and In Vivo Activities Against Leishmania donovani. Regenerative Engineering and Translational Medicine, 2018, 4, 11-20.	2.9	2
30	Phase solubility studies and anti-Trichomonas vaginalis activity evaluations of metronidazole and methylated Î²-cyclodextrin complexes: Comparison of CRYSMEB and RAMEB. Experimental Parasitology, 2018, 189, 72-75.	1.2	10
31	Enrichment of free-living amoebae in biofilms developed at upper water levels in drinking water storage towers: An inter- and intra-seasonal study. Science of the Total Environment, 2018, 633, 157-166.	8.0	21
32	Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road communities in Loreto (Peru). Journal of Ethnopharmacology, 2018, 210, 372-385.	4.1	30
33	In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion. Experimental Parasitology, 2018, 192, 85-92.	1.2	27
34	Surface-dependent endocytosis of poly(isobutylcyanoacrylate) nanoparticles by Trichomonas vaginalis. International Journal of Pharmaceutics, 2018, 548, 276-287.	5.2	18
35	Polysorbate Surfactants as Drug Carriers: Tween 20-Amphotericin B Conjugates as Anti-Fungal and Anti-Leishmanial Agents. Current Drug Delivery, 2018, 15, 1028-1037.	1.6	11
36	Revisiting Previously Investigated Plants: A Molecular Networking-Based Study of Geissospermum laeve. Journal of Natural Products, 2017, 80, 1007-1014.	3.0	45

#	Article	IF	Citations
37	Anti-fungal and anti-leishmanial activities of pectin-amphotericin B conjugates. Journal of Drug Delivery Science and Technology, 2017, 39, 1-7.	3.0	21
38	Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model. Pharmaceutical Research, 2017, 34, 1067-1082.	3.5	24
39	Cyclodextrin-mediated self-associating chitosan micro-platelets act as a drug booster against Candida glabrata mucosal infection in immunocompetent mice. International Journal of Pharmaceutics, 2017, 519, 381-389.	5.2	13
40	Biochemical analysis of leishmanial and human GDP-Mannose Pyrophosphorylases and selection of inhibitors as new leads. Scientific Reports, 2017, 7, 751.	3.3	24
41	Strategies for Prevention and Treatment of Trichomonas vaginalis Infections. Clinical Microbiology Reviews, 2017, 30, 811-825.	13.6	81
42	Antiplasmodial Securinega alkaloids from Phyllanthus fraternus: Discovery of natural (+)-allonorsecurinine. Tetrahedron Letters, 2017, 58, 3754-3756.	1.4	19
43	InÂvitro evaluation of antimicrobial agents on Acanthamoeba sp. and evidence of a natural resilience to amphotericin B. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 328-336.	3.4	19
44	Polyamine-based analogs and conjugates as antikinetoplastid agents. European Journal of Medicinal Chemistry, 2017, 139, 982-1015.	5.5	15
45	Synthesis and in vitro antikinetoplastid activity of polyamineâ€“hydroxybenzotriazole conjugates. Bioorganic and Medicinal Chemistry, 2017, 25, 84-90.	3.0	8
46	Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Leishmania and Chlamydiales. Chemico-Biological Interactions, 2017, 267, 96-103.	4.0	25
47	In situ forming pluronicÂ® F127/chitosan hydrogel limits metronidazole transmucosal absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 143-147.	4.3	45
48	ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments. Scientific Reports, 2017, 7, 15567.	3.3	13
49	In Silico Mining for Antimalarial Structure-Activity Knowledge and Discovery of Novel Antimalarial Curcuminoids. Molecules, 2016, 21, 853.	3.8	16
50	Antiplasmodial activity of selected medicinal plants used to treat malaria in Ghana. Parasitology Research, 2016, 115, 3185-3195.	1.6	31
51	Leishmania hijacking of the macrophage intracellular compartments. FEBS Journal, 2016, 283, 598-607.	4.7	43
52	Simple and efficient synthesis of $$5'$$ 5 â€² -aryl- $$5'$$ 5 â€² -deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities. Molecular Diversity, 2016, 20, 507-519.	3.9	14
53	Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors. European Journal of Medicinal Chemistry, 2016, 109, 173-186.	5.5	17
54	Comparative study of structural models of Leishmania donovani and human GDP-mannose pyrophosphorylases. European Journal of Medicinal Chemistry, 2016, 107, 109-118.	5.5	12

#	Article	IF	Citations
55	Freeze-Dried Microemulsion Containing Amphotericin B for Leishmaniasis Treatment: An Overview. Journal of Colloid Science and Biotechnology, 2016, 5, 55-68.	0.2	3
56	Biodereplication approach for antimalarial drugs in complex extracts mixtures: active compounds from the insect Pyrrhocoris apterus. Planta Medica, 2016, 81, S1-S381.	1.3	0
57	Cell line-dependent cytotoxicity of poly(isobutylcyanoacrylate) nanoparticles coated with chitosan and thiolated chitosan: Insights from cultured human epithelial HeLa, Caco2/TC7 and HT-29/MTX cells. International Journal of Pharmaceutics, 2015, 491, 17-20.	5.2	16
58	Drug-Free Chitosan Coated Poly(isobutylcyanoacrylate) Nanoparticles Are Active Against Trichomonas vaginalis and Non-Toxic Towards Pig Vaginal Mucosa. Pharmaceutical Research, 2015, 32, 1229-1236.	3.5	39
59	In vitro and in vivo antileishmanial properties of a 2-n-propylquinoline hydroxypropyl Î²-cyclodextrin formulation and pharmacokinetics via intravenous route. Biomedicine and Pharmacotherapy, 2015, 76, 127-133.	5.6	25
60	The unexpected increase of clotrimazole apparent solubility using randomly methylated Î²â€cyclodextrin. Journal of Molecular Recognition, 2015, 28, 96-102.	2.1	13
61	Medicinal plants and finished marketed herbal products used in the treatment of malaria in the Ashanti region, Ghana. Journal of Ethnopharmacology, 2015, 172, 333-346.	4.1	70
62	New heterocyclic compounds: Synthesis and antitrypanosomal properties. Bioorganic and Medicinal Chemistry, 2015, 23, 5168-5174.	3.0	18
63	VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. Journal of Infectious Diseases, 2015, 212, 1439-1448.	4.0	51
64	Synthesis of 5-isoxazol-3-yl-pyrimidine nucleosides as potential antileishmanial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2617-2620.	2.2	13
65	Bioactive phloroglucinols from Mallotus oppositifolius. FÃ¬toterapÃ¬Ã¢, 2015, 107, 100-104.	2.2	14
66	Gelation and micellization behaviors of pluronicÂ® F127 hydrogel containing poly(isobutylcyanoacrylate) nanoparticles specifically designed for mucosal application. Colloids and Surfaces B: Biointerfaces, 2015, 135, 669-676.	5.0	28
67	â€œSqualenoylcurcuminâ€•Nanoassemblies as Waterâ€Dispersible Drug Candidates with Antileishmanial Activity. ChemMedChem, 2015, 10, 411-418.	3.2	20
68	Design, synthesis and in vitro antikinetoplastid evaluation of N-acylated putrescine, spermidine and spermine derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 207-209.	2.2	9
69	Targeting sterol metabolism for the development of antileishmanials. Trends in Parasitology, 2015, 31, 5-7.	3.3	3
70	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 2015, 4, 34.	1.6	41
71	Synthesis and Antileishmanial Activity of Pyrimidine Nucleoside- Chalcone Hybrids. Chinese Journal of Organic Chemistry, 2015, 35, 1335.	1.3	4
72	The auto-inhibitory domain and ATP-independent microtubule-binding region of Kinesin heavy chain are major functional domains for transport in theDrosophilagermline. Development (Cambridge), 2014, 141, 176-186.	2.5	37

#	Article	IF	Citations
73	Antileishmanial activity of Opuntia ficus-indica fractions. Biomedicine and Preventive Nutrition, 2014, 4, 101-104.	0.9	6
74	Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism. Biomedicine and Pharmacotherapy, 2014, 68, 893-897.	5.6	9
75	Development of antileishmanial lipid nanocomplexes. Biochimie, 2014, 107, 143-153.	2.6	17
76	Investigation of the complexation of albendazole with cyclodextrins for the design of new antiparasitic formulations. Carbohydrate Research, 2014, 398, 50-55.	2.3	29
77	Adsorption of Antisense Oligonucleotides Targeting Malarial Topoisomerase II on Cationic Nanoemulsions Optimized by a Full Factorial Design. Current Topics in Medicinal Chemistry, 2014, 14, 1161-1171.	2.1	7
78	New Anti-Malarial Drugs: Who Cares?. Current Topics in Medicinal Chemistry, 2014, 14, 1637-1642.	2.1	4
79	The auto-inhibitory domain and ATP-independent microtubulebinding region of Kinesin heavy chain are major functional domains for transport in the Drosophila germline. Journal of Cell Science, 2014, 127, e1-e1.	2.0	0
80	Strategies for the design of orally bioavailable antileishmanial treatments. International Journal of Pharmaceutics, 2013, 454, 539-552.	5.2	50
81	Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin Bâ€“miltefosine-loaded nanocochleates. Colloids and Surfaces B: Biointerfaces, 2013, 106, 224-233.	5.0	28
82	Synthesis and antiprotozoal activity of original porphyrin precursors and derivatives. European Journal of Medicinal Chemistry, 2013, 67, 158-165.	5.5	18
83	Introduction of methionine mimics on 3-arylthiophene: influence on protein farnesyltransferase inhibition and on antiparasitic activity. MedChemComm, 2013, 4, 1034.	3.4	7
84	Antiprotozoal activity of ferroquine. Parasitology Research, 2013, 112, 665-669.	1.6	15
85	Drug Targets, Drug Effectors, and Drug Targeting and Delivery. , 2013, , 321-350.		0
86	Synthesis of novel guttiferone A derivatives: In-vitro evaluation toward Plasmodium falciparum, Trypanosoma brucei and Leishmania donovani. European Journal of Medicinal Chemistry, 2013, 65, 284-294.	5.5	25
87	Clotrimazole-loaded nanostructured lipid carrier hydrogels: Thermal analysis and in vitro studies. International Journal of Pharmaceutics, 2013, 454, 695-702.	5.2	70
88	Antimalarial Activity of Axidjiferosides, New Î²-Galactosylceramides from the African Sponge Axinyssa djiferi. Marine Drugs, 2013, 11, 1304-1315.	4.6	21
89	In silicoanalysis of a therapeutic target inLeishmania infantum: the guanosine-diphospho-D-mannose pyrophosphorylase. Parasite, 2012, 19, 63-70.	2.0	11
90	LeishmaniaResistance to Miltefosine Associated with Genetic Marker. Emerging Infectious Diseases, 2012, 18, 704-706.	4.3	86

#	Article	IF	Citations
91	In vitro antileishmanial and antitrypanosomal activities of five medicinal plants from Burkina Faso. Parasitology Research, 2012, 110, 1779-1783.	1.6	24
92	Comparison of electrospray ionization, atmospheric pressure chemical ionization and atmospheric pressure photoionization for a lipidomic analysis of Leishmania donovani. Journal of Chromatography A, 2012, 1242, 75-83.	3.7	44
93	Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives. European Journal of Medicinal Chemistry, 2012, 52, 44-50.	5.5	29
94	Synthesis and anti-leishmanial activity of 1-aryl-Î²-carboline derivatives against Leishmania donovani. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3905-3907.	2.2	30
95	Diarylheptanoid Glucosides from Pyrostria major and Their Antiprotozoal Activities. European Journal of Organic Chemistry, 2012, 2012, 1039-1046.	2.4	17
96	Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis. Analytical and Bioanalytical Chemistry, 2012, 402, 1169-1182.	3.7	55
97	In vitro antileishmanial properties of new flavonoids against Leishmania donovani. Biomedicine and Preventive Nutrition, 2011, 1, 168-171.	0.9	15
98	In Vitro Activities of New 2-Substituted Quinolines against Leishmania donovani. Antimicrobial Agents and Chemotherapy, 2011, 55, 1777-1780.	3.2	42
99	In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCl: a diglyceride prodrug. Journal of Pharmacy and Pharmacology, 2011, 41, 191-193.	2.4	17
100	Antileishmanial activity of a formulation of 2-n-propylquinoline by oral route in mice model. Parasite, 2011, 18, 333-336.	2.0	13
101	Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance. Parasite, 2011, 18, 115-119.	2.0	79
102	Membrane lipidomics for the discovery of new antiparasitic drug targets. Trends in Parasitology, 2011, 27, 496-504.	3.3	18
103	Cationic nanoemulsion as a delivery system for oligonucleotides targeting malarial topoisomerase II. International Journal of Pharmaceutics, 2011, 416, 402-409.	5.2	29
104	In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. Journal of Pharmacy and Pharmacology, 2010, 55, 647-652.	2.4	35
105	Practical and efficient synthesis of pyrano[3,2-c]pyridone, pyrano[4,3-b]pyran and their hybrids with nucleoside as potential antiviral and antileishmanial agents. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 809-813.	2.2	124
106	Mechanism of interaction of sitamaquine with Leishmania donovani. Journal of Antimicrobial Chemotherapy, 2010, 65, 2548-2555.	3.0	21
107	Solvent-Free Synthesis of Pyrimidine Nucleoside-Aminophosphonate Hybrids and Their Biological Activity Evaluation. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 616-627.	1.1	20
108	Drosophila PAT1 is required for Kinesin-1 to transport cargo and to maximize its motility. Development (Cambridge), 2010, 137, 2763-2772.	2.5	50

#	Article	IF	Citations
109	Drosophila PAT1 is required for Kinesin-1 to transport cargo and to maximize its motility. Journal of Cell Science, 2010, 123, e1-e1.	2.0	0
110	Antifungal and Anthelmintic Activities ofCleistopholis patens(Annonaceae). Planta Medica, 2009, 75, 1143-1145.	1.3	4
111	Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes. Journal of Antimicrobial Chemotherapy, 2009, 64, 993-1001.	3.0	42
112	Perspectives for parasitology and parasitology networks in Europe. Trends in Parasitology, 2009, 25, 293-295.	3.3	5
113	Ionic liquid mediated and promoted eco-friendly preparation of thiazolidinone and pyrimidine nucleosideâ€“thiazolidinone hybrids and their antiparasitic activities. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6280-6283.	2.2	84
114	A novel 1-indanone isolated from Uvaria afzelii roots. Natural Product Research, 2009, 23, 909-915.	1.8	32
115	Cellular Transport and Lipid Interactions of Miltefosine. Current Drug Metabolism, 2009, 10, 247-255.	1.2	53
116	Comparison between charged aerosol detection and light scattering detection for the analysis of Leishmania membrane phospholipids. Journal of Chromatography A, 2008, 1209, 88-94.	3.7	85
117	Antifungal canthin-6-one series accumulate in lipid droplets and affect fatty acid metabolism in Saccharomyces cerevisiae. Biomedicine and Pharmacotherapy, 2008, 62, 99-103.	5.6	23
118	Selection and phenotype characterisation of sitamaquine-resistant promastigotes of Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 164-167.	5.6	25
119	In vitro antileishmanial activity of fluoro-artemisinin derivatives against Leishmania donovani. Biomedicine and Pharmacotherapy, 2008, 62, 462-465.	5.6	20
120	Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials. Biomedicine and Pharmacotherapy, 2008, 62, 684-689.	5.6	38
121	Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 246-252.	2.6	35
122	In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomedicine and Pharmacotherapy, 2007, 61, 186-188.	5.6	33
123	Antileishmanial 2-substituted quinolines: In vitro behaviour towards biological components. Biomedicine and Pharmacotherapy, 2007, 61, 441-450.	5.6	22
124	Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition. Biomedicine and Pharmacotherapy, 2007, 61, 499-504.	5.6	11
125	The Ugi reaction in the generation of new nucleosides as potential antiviral and antileishmanial agents. Bioorganic Chemistry, 2007, 35, 121-136.	4.1	27
126	Amphotericin B-Gum Arabic Conjugates: Synthesis, Toxicity, Bioavailability, and Activities Against Leishmania and Fungi. Pharmaceutical Research, 2007, 24, 971-980.	3.5	75

#	Article	IF	Citations
127	Synthesis ofÂoxysterols andÂnitrogenous sterols with antileishmanial andÂtrypanocidal activities. European Journal of Medicinal Chemistry, 2006, 41, 1109-1116.	5.5	24
128	Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5047-5051.	2.2	20
129	Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 815-820.	2.2	172
130	Bioactive properties of plant species ingested by chimpanzees (Pan troglodytes schweinfurthii) in the Kibale National Park, Uganda. American Journal of Primatology, 2006, 68, 51-71.	1.7	58
131	Mechanisms of Drug Action and Drug Resistance in Leishmania as Basis for Therapeutic Target Identification and Design of Antileishmanial Modulators. Current Topics in Medicinal Chemistry, 2006, 6, 539-550.	2.1	39
132	Interaction between Miltefosine and Amphotericin B: Consequences for Their Activities towards Intestinal Epithelial Cells and Leishmania donovani Promastigotes In Vitro. Antimicrobial Agents and Chemotherapy, 2006, 50, 3793-3800.	3.2	30
133	Synthesis and in vitro antileishmanial activity of 5-substituted-2â€²-deoxyuridine derivatives. Bioorganic Chemistry, 2005, 33, 439-447.	4.1	36
134	Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases. Antimicrobial Agents and Chemotherapy, 2005, 49, 4950-4956.	3.2	86
135	Alteration of Fatty Acid and Sterol Metabolism in Miltefosine-Resistant Leishmania donovani Promastigotes and Consequences for Drug-Membrane Interactions. Antimicrobial Agents and Chemotherapy, 2005, 49, 2677-2686.	3.2	119
136	Screening of New Caledonian and Vanuatu medicinal plants for antiprotozoal activity. Journal of Ethnopharmacology, 2005, 96, 569-575.	4.1	17
137	N-acetyl-Î²-d-hexosaminidase from Trichomonas vaginalis: substrate specificity and activity of inhibitors. Biomedicine and Pharmacotherapy, 2005, 59, 245-248.	5.6	8
138	Antileishmanial andÂtrypanocidal activities ofÂnew miltefosine liposomal formulations. Biomedicine and Pharmacotherapy, 2005, 59, 545-550.	5.6	35
139	Cloning of S -Adenosyl- l -Methionine:C-24-Î”-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant Promastigotes. Antimicrobial Agents and Chemotherapy, 2004, 48, 2409-2414.	3.2	65
140	Antiplasmodial Activity of Acetogenins and Inhibitory Effect onPlasmodium falciparumAdenylate Translocase. Journal of Chemotherapy, 2004, 16, 350-356.	1.5	17
141	Miltefosine Induces Apoptosis-Like Death in Leishmania donovani Promastigotes. Antimicrobial Agents and Chemotherapy, 2004, 48, 852-859.	3.2	297
142	In vitro antileishmanial activity of acetogenins from Annonaceae. Biomedicine and Pharmacotherapy, 2004, 58, 388-392.	5.6	24
143	Hexadecylphosphocholine interaction with lipid monolayers. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1661, 212-218.	2.6	81
144	Antiparasitic activities of medicinal plants used in Ivory Coast. Journal of Ethnopharmacology, 2004, 90, 91-97.	4.1	154

#	Article	IF	Citations
145	Efficacy and Pharmacokinetics of Intravenous Nanocapsule Formulations of Halofantrine in Plasmodium berghei -Infected Mice. Antimicrobial Agents and Chemotherapy, 2004, 48, 1222-1228.	3.2	90
146	Acaricidal Activity of Tonka Bean Extracts. Synthesis and Structureâ^'Activity Relationships of Bioactive Derivatives. Journal of Natural Products, 2003, 66, 690-692.	3.0	28
147	Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2003, 47, 3774-3779.	3.2	61
148	Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations. Antimicrobial Agents and Chemotherapy, 2002, 46, 1597-1601.	3.2	23
149	In Vitro Antileishmanial Activity of Amphotericin B Loaded in Poly(Îµ-Caprolactone) Nanospheres. Journal of Drug Targeting, 2002, 10, 593-599.	4.4	87
150	The chitinase system from Trichomonas vaginalis as a potential target for antimicrobial therapy of urogenital trichomoniasis. Biomedicine and Pharmacotherapy, 2002, 56, 503-510.	5.6	18
151	Synthesis and trichomonacidal activity of perketals and hydroperoxides. Il Farmaco, 2002, 57, 457-462.	0.9	2
152	Characterisation of atovaquone resistance in Leishmania infantum promastigotes. International Journal for Parasitology, 2002, 32, 1043-1051.	3.1	27
153	Klaivanolide, an antiprotozoal lactone from Uvaria klaineana. Phytochemistry, 2002, 59, 885-888.	2.9	31
154	Structure-activity relationships for new organometallic complexes active against bloodstream forms of Trypanosoma brucei brucei. Parasitology Research, 2001, 87, 566-569.	1.6	1
155	Synthesis and in vitro Trichomonacidal activities of some new dialkylperoxides and 1,2,4-trioxanes. European Journal of Medicinal Chemistry, 2001, 36, 837-842.	5.5	25
156	Purification of N-Acetyl-Î²-d-hexosaminidase from Trichomonas vaginalis. Experimental Parasitology, 2001, 97, 169-172.	1.2	3
157	In vivoantileishmanial action of Ir-(COD)-pentamidine tetraphenylborate onLeishmania donovaniandLeishmania majormouse models. Parasite, 2000, 7, 103-108.	2.0	23
158	Contribution of Dithiol Ligands to In Vitro and In Vivo Trypanocidal Activities of Dithiaarsanes and Investigation of Ligand Exchange in an Aqueous Solution. Antimicrobial Agents and Chemotherapy, 2000, 44, 2954-2961.	3.2	38
159	Squamocin and Benzyl Benzoate, Acaricidal Components ofUvaria pauci-ovulataBark Extracts. Planta Medica, 2000, 66, 173-175.	1.3	20
160	In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188. Antimicrobial Agents and Chemotherapy, 2000, 44, 2190-2192.	3.2	34
161	A New Photometric Assay with Bromocresol Purple for Testing in vitro Antitrichomonal Activity in Aerobic Environment. Arzneimittelforschung, 1999, 49, 51-55.	0.4	4
162	SYNTHESIS AND PROTOZOOCIDAL ACTIVITY OF NEW 1,4-NAPHTHOQUINONES. Heterocyclic Communications, 1999, 5, .	1.2	5

#	Article	IF	Citations
163	Recent strategies for the chemotherapy of visceral leishmaniasis. Current Opinion in Infectious Diseases, 1999, 12, 559-564.	3.1	8
164	Synthesis and biological evaluation of ureido and thioureido derivatives of 2-amino-2-deoxy-d-glucose and related aminoalcohols as N-acetyl-Î²-d-hexosaminidase inhibitors. Carbohydrate Research, 1998, 314, 47-63.	2.3	7
165	Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani. Acta Tropica, 1998, 70, 239-245.	2.0	20
166	Chitinolytic activities inTrichomonas vaginalis. Parasite, 1998, 5, 75-78.	2.0	11
167	Mechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes. Antimicrobial Agents and Chemotherapy, 1998, 42, 352-357.	3.2	181
168	Studies on lipidomimetic derivatives of Î±-difluoromethylornithine (DFMO) to enhance the bioavailability in aTrypanosoma b. bruceimurine trypanosomiasis model. Parasite, 1998, 5, 239-246.	2.0	5
169	Tissue distribution and metabolism in rat of an ethynesulphonamide with filaricidal activity. Xenobiotica, 1997, 27, 73-85.	1.1	2
170	Lymphotropic antifilarial agents derived from closantel and chlorambucil. International Journal for Parasitology, 1997, 27, 443-447.	3.1	11
171	Effect of chronic trypanosomiasis on the bioavailability of Î±-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. Parasitology Research, 1997, 83, 386-389.	1.6	3
172	Isolation of bloodstream trypanosomes by sedimentation field-flow fractionation. Journal of Separation Science, 1997, 9, 469-477.	1.0	11
173	Kinetic parameters of N-acetylglucosaminidase in adult femaleNippostrongylus brasiliensisby a quantitative colorimetric micromethod. Parasite, 1996, 3, 115-118.	2.0	0
174	Antileishmanial activity of rac-1-dodecy1-2-octanamido-2-deoxy-glycerophosphocholine, a new dialkylglycerophosphocholine, in vitro. Annals of Tropical Medicine and Parasitology, 1996, 90, 559-561.	1.6	4
175	The effect of spiroarsoranes on Trypanosoma brucei brucei and T. b. rhodesiense. Parasitology Research, 1996, 82, 477-480.	1.6	2
176	Purification and characterization of lactate dehydrogenase isoenzymes 1 and 2 from Molinema dessetae (Nematoda: Filarioidea). Parasitology Research, 1996, 82, 672-680.	1.6	11
177	Synthesis and protozoocidal activities of quinones. European Journal of Medicinal Chemistry, 1996, 31, 507-511.	5.5	14
178	Plasmodium berghei mouse model: antimalarial activity of new alkaloid salts and of thiosemicarbazone and acridine derivatives. Tropical Medicine and International Health, 1996, 1, 379-384.	2.3	16
179	Selective elution and purification of living Trichomonas vaginalis using gravitational field-flow fractionation. Biomedical Applications, 1995, 664, 444-448.	1.7	38
180	Synthesis and nematocidal activities of new analogs of pyrantel. European Journal of Medicinal Chemistry, 1995, 30, 509-513.	5.5	8

#	Article	IF	Citations
181	Synthesis, antifungal and nematocidal activities of thioureines with an aminoester sequence. European Journal of Medicinal Chemistry, 1995, 30, 801-807.	5.5	5
182	The incorporation of N,Nâ€²- bis(2,3-dihydroxybenzoyl)-1,6 diazahexane or octane as the ligands of spiroarsoranes: their effect on trypanocidal activity. Acta Tropica, 1995, 59, 237-241.	2.0	2
183	Action of DNA-gyrase inhibiting derivatives of 4-oxo-1, 4-dihydro-3-pyridinecarboxylic acid against Trypanosoma brucei. International Journal for Parasitology, 1995, 25, 403-405.	3.1	5
184	Cytotoxic and Antiparasitic Activity fromAnnona senegalensisSeeds*. Planta Medica, 1994, 60, 538-540.	1.3	47
185	Isoenzymatic diagnosis of filariae: a method for separation of lactate dehydrogenase isoenzymes from Molinema dessetae (Nematoda: Filarioidea). Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1994, 109, 451-457.	0.2	5
186	Synthesis and nematocidal activities of arylvinyltetrahydropyrimidines. European Journal of Medicinal Chemistry, 1993, 28, 979-982.	5.5	4
187	Research for new filaricides by using phosphoenolpyruvate-carboxylase from Molinema dessetae (Nematoda: Filarioidea) as biochemical target. International Journal for Parasitology, 1993, 23, 697-698.	3.1	2
188	In vitro antifilarial evaluation of phenoxycyclohexane derivatives. Annals of Tropical Medicine and Parasitology, 1993, 87, 469-476.	1.6	9
189	SynthÃ¨se, activitÃ© antiparasitaire et antifongique de thiourÃ©ines Ã motif aminoacide. European Journal of Medicinal Chemistry, 1991, 26, 723-727.	5.5	4
190	Antiparasitic Activity ofAnnona muricataandAnnona cherimoliaSeeds. Planta Medica, 1991, 57, 434-436.	1.3	50
191	Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. F1000Research, 0, 4, 34.	1.6	7